Abstract
Simultaneous modulation of multifaceted toxicity arising from neuroinflammation, oxidative stress, and mitochondrial dysfunction represents a valuable therapeutic strategy to tackle Alzheimer's disease. Among the significant hallmarks of the disorder, Aβ protein and its aggregation products are well-recognised triggers of the neurotoxic cascade. In this study, by tailored modification of the curcumin-based lead compound 1, we aimed at developing a small library of hybrid compounds targeting Aβ protein oligomerisation and the consequent neurotoxic events. Interestingly, from in vitro studies, analogues 3 and 4, bearing a substituted triazole moiety, emerged as multifunctional agents able to counteract Aβ aggregation, neuroinflammation and oxidative stress. In vivo proof-of-concept evaluations, performed in a Drosophila oxidative stress model, allowed us to identify compound 4 as a promising lead candidate.
| Original language | English |
|---|---|
| Article number | 115297 |
| Journal | European Journal of Medicinal Chemistry |
| Volume | 252 |
| DOIs | |
| Publication status | Published - 5 Apr 2023 |
| Externally published | Yes |
Keywords
- Alzheimer's disease
- Amyloid beta oligomers
- Curcumin analogues
- Drosophila Melanogaster model
- Natural products
- Neuroinflammation
- Oxidative stress
Fingerprint
Dive into the research topics of 'Targeting the multifaceted neurotoxicity of Alzheimer's disease by tailored functionalisation of the curcumin scaffold'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver